# OptimizeRx Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/OptimizeRx Corp). ## Overview OptimizeRx Corp is a U.S.-based digital healthcare technology company that connects life sciences brands with healthcare professionals and patients through proprietary messaging, audience, and media execution tools. Its platform is built around point-of-care distribution, omnichannel patient outreach, and data-driven audience activation delivered through EHR, ePrescribing, and digital media channels. ## Products & services • Dynamic Audience Activation Platform (DAAP) • Micro-Neighborhood® Targeting (MNT) • Profiler audience profiling • HCP point-of-care banner messaging • Patient support and affordability messaging • Omnichannel media execution for DTC campaigns - **Audience Development** (30%) — Tools that identify and prioritize HCP and patient audiences for targeted campaigns. - **Audience Activation and Media Execution** (45%) — Messaging and media delivery across EHR, eRx, social, CTV/OTT, and other channels. - **Audience Profiling** (10%) — Profiler insights used to plan channels, partners, and campaign strategy. - **Consumer Omnichannel Solutions** (15%) — Patient-facing media execution through digital and addressable media channels. - Dynamic Audience Activation Platform (DAAP) - Micro-Neighborhood® Targeting (MNT) - Profiler audience profiling - HCP point-of-care banner messaging - Patient support and affordability messaging - Omnichannel media execution for DTC campaigns ## Customers OptimizeRx sells primarily to pharmaceutical and other life sciences manufacturers that need to reach physicians, pharmacists, and patients with brand, support, and affordability messages. Its customer base is concentrated among large pharma companies with multiple brands, while the underlying audiences include HCPs at the point of care and brand-eligible patients across digital channels. - **Pharmaceutical manufacturers** (primary) — Buy HCP and patient engagement solutions to promote brands, support access, and drive prescribing. - **Life sciences marketing teams** (primary) — Use audience profiling and media execution tools to plan and run targeted campaigns. - **Patient support program sponsors** (secondary) — Buy affordability, co-pay, and support messaging to improve access and adherence. - **Consumer health advertisers** (secondary) — Use DTC omnichannel tools to reach brand-eligible patients across digital media. - Large pharmaceutical manufacturers buying brand and support messaging - Life sciences marketers seeking HCP point-of-care reach - Teams running patient affordability and adherence campaigns - Brands needing audience data and campaign planning support - Customers that value targeted, measurable omnichannel execution ## Geography OptimizeRx is headquartered in the United States and serves a predominantly U.S.-based healthcare advertising market. Its technology and operations are also supported by teams in Croatia, India, and Ukraine, reflecting a distributed development and support model rather than a broad physical sales footprint. - Headquartered in the United States - Primary commercial market is U.S. life sciences advertising - Technology and systems teams in the U.S. and Croatia - Contractors in India, Ukraine, the U.S., and Croatia - Operations depend on U.S. healthcare data and channel partners ## Strategy OptimizeRx is focused on expanding from point-of-care messaging into a broader platform that combines audience development, audience creation, and media execution. The company is also emphasizing enterprise relationships, subscription-like data services, and cross-selling across HCP and consumer channels to make revenue more predictable and deepen customer penetration. - **Grow DAAP adoption** (short-term) — DAAP uses predictive analytics to target HCPs and patients more precisely and can support higher-value engagements. - **Expand omnichannel execution** (medium-term) — Adding consumer media channels broadens the addressable market beyond point-of-care messaging. - **Shift toward recurring data services** (medium-term) — Subscription-based data services can improve revenue predictability and customer retention. - **Deepen enterprise customer relationships** (short-term) — Larger multi-brand pharma accounts can support cross-sell and expansion within existing customers. - Expand enterprise-level relationships with existing pharma customers - Grow DAAP and other higher-value data-driven offerings - Broaden from HCP messaging into consumer omnichannel execution - Increase subscription-style revenue visibility from data services - Use land-and-expand selling to deepen customer penetration ## Risks The business depends on a concentrated base of large pharmaceutical customers and on channel partnerships with EHR and ePrescribing platforms, so customer loss or partner disruption can materially affect revenue. It also faces cybersecurity, privacy, and regulatory risks because its platform handles healthcare data and operates in a heavily regulated pharmaceutical marketing environment. - **Customer concentration** [high] — A small number of large pharmaceutical customers account for a large share of revenue, so account loss or reduced spend can quickly affect results. - **Channel partner dependence** [high] — The company relies on EHR and eRx platforms to distribute messages at the point of care, so partner disruption can impair delivery and revenue. - **Cybersecurity and data privacy** [high] — The platform processes healthcare and patient-related information, making breaches or system failures costly and reputationally damaging. - **Regulatory and advertising restrictions** [medium] — Pharmaceutical marketing is subject to healthcare, privacy, and promotional rules that can limit campaign design and data use. - **Seasonality of pharma marketing spend** [medium] — Brand marketing budgets are often weighted toward year-end, creating quarter-to-quarter volatility in demand and revenue. - Revenue concentration among a small number of large pharma customers - Dependence on EHR and eRx channel partners for point-of-care delivery - Cybersecurity and data privacy exposure from healthcare information handling - Regulatory risk around pharmaceutical advertising and patient data use - Seasonality in pharma marketing budgets can shift quarterly results ## Accounting OptimizeRx’s reported results depend heavily on revenue recognition timing for campaign and data-service arrangements, as well as the related revenue-share expense paid to channel partners. Investors should also watch estimates tied to acquired intangibles, internally developed software, stock-based compensation, and the valuation allowance for deferred tax assets, since these judgments can materially affect earnings and balance-sheet values. - **Revenue recognition and revenue-share expense** — Timing and mix can move quarterly revenue and cost of revenues - **Internally developed software capitalization** — Impacts reported operating income and intangible assets - **Acquired intangibles and goodwill** — Can create noncash impairment charges - **Stock-based compensation** — Affects operating expenses and diluted share count - **Deferred tax asset valuation allowance** — Can materially affect income tax benefit/expense - Revenue recognition timing for campaign and data-service contracts - Revenue-share expense tied to channel partner arrangements - Capitalization of internally developed software - Valuation of acquired intangibles and goodwill - Stock-based compensation and deferred tax asset allowance --- *Last updated: 2026-04-29T04:44:11.109400+00:00*